Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 12,454	$ 26,371
Short-term investments – available for sale	172,445	175,732
Prepaid clinical trial and preclinical study costs	8,012	7,806
Prepaid expenses and other current assets	388	619
Total current assets	193,299	210,528
Right-of-use assets	1,632	25
Deferred financing costs	64	76
Deposits	33	33
Total assets	195,028	210,662
Current liabilities:
Accounts payable	3,119	1,444
Other accrued liabilities	7,999	7,305
Lease liability, current	150	29
Total current liabilities	11,268	8,778
Lease liability, net of current portion	1,490
Total long-term liabilities	1,490
Total liabilities	12,758	8,778
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2022 and December 31, 2021; 77,373,712 and 78,248,401 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	1	1
Additional paid-in capital	428,086	425,614
Accumulated deficit	(239,285)	(223,182)
Accumulated other comprehensive loss	(1,411)	(549)
Treasury stock at cost, 1,464,217 shares at March 31, 2022, no shares at December 31, 2021	(5,121)
Total stockholders’ equity	182,270	201,884
Total liabilities and stockholders’ equity	$ 195,028	$ 210,662